Sopharma AD Total Assets
Sopharma AD total assets. Based on the latest financial reports, Sopharma AD (SPH) holds total assets worth zł2.02 Billion PLN (≈ $555.35 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how efficiently does Sopharma AD generate cash for how efficiently the company converts equity into cash flow.
Total Assets of Sopharma AD (2011–2024)
Total assets of Sopharma AD from 2011 to 2024. This chart illustrates how Sopharma AD's total assets have evolved over time, based on quarterly financial data. See current stock price of Sopharma AD for real-time trading data and today's change.
Sopharma AD - Asset Composition Analysis
Sopharma AD Total Assets Breakdown (December 2024)
Sopharma AD total assets breakdown as of December 2024. Sopharma AD's total assets of zł2.02 Billion consist of 47.3% current assets and 52.7% non-current assets. Explore SPH working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 2.0% |
| Accounts Receivable | zł334.83 Million | 18.6% |
| Inventory | zł451.41 Million | 25.1% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł257.28 Million | 14.3% |
| Goodwill | zł5.54 Million | 0.3% |
Asset Composition Trend (2011–2024)
This chart illustrates how Sopharma AD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sopharma AD's current assets represent 47.3% of total assets in 2024, a decrease from 56.5% in 2011.
- Cash Position: Cash and equivalents constituted 2.0% of total assets in 2024, down from 4.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 3.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 25.1% of total assets.
Sopharma AD Competitors by Total Assets
Key competitors of Sopharma AD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Liaoning Cheng Da Co Ltd
SHG:600739
|
China | CN¥50.48 Billion |
|
Mayne Pharma Group Ltd
AU:MYX
|
Australia | AU$1.01 Billion |
|
Millennium Pharmacon International
JK:SDPC
|
Indonesia | Rp1.90 Trillion |
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
|
China | CN¥21.18 Billion |
|
Sigma Healthcare Ltd
AU:SIG
|
Australia | AU$8.74 Billion |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$8.80 Billion |
|
Paragon Care Ltd
AU:PGC
|
Australia | AU$1.31 Billion |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
|
Brazil | R$5.64 Billion |
Sopharma AD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.31 | 1.43 | 1.12 |
| Quick Ratio | 0.70 | 0.73 | 0.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł245.60 Million | zł249.15 Million | zł67.73 Million |
Sopharma AD - Advanced Valuation Insights
This section examines the relationship between Sopharma AD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.13 |
| Latest Market Cap to Assets Ratio | 1.15 |
| Asset Growth Rate (YoY) | 18.6% |
| Total Assets | zł1.80 Billion |
| Market Capitalization | $2.07 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Sopharma AD's assets above their book value (1.15x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Sopharma AD's assets grew by 18.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sopharma AD (2011–2024)
The table below shows the annual total assets of Sopharma AD from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł1.80 Billion ≈ $494.36 Million |
+18.63% |
| 2023-12-31 | zł1.51 Billion ≈ $416.72 Million |
+20.57% |
| 2022-12-31 | zł1.26 Billion ≈ $345.61 Million |
+4.22% |
| 2021-12-31 | zł1.20 Billion ≈ $331.63 Million |
-2.99% |
| 2020-12-31 | zł1.24 Billion ≈ $341.85 Million |
+5.69% |
| 2019-12-31 | zł1.18 Billion ≈ $323.45 Million |
+16.29% |
| 2018-12-31 | zł1.01 Billion ≈ $278.13 Million |
+3.05% |
| 2017-12-31 | zł980.73 Million ≈ $269.91 Million |
+14.14% |
| 2016-12-31 | zł859.22 Million ≈ $236.47 Million |
+2.82% |
| 2015-12-31 | zł835.63 Million ≈ $229.98 Million |
+2.23% |
| 2014-12-31 | zł817.36 Million ≈ $224.95 Million |
+4.42% |
| 2013-12-31 | zł782.79 Million ≈ $215.43 Million |
+5.01% |
| 2012-12-31 | zł745.42 Million ≈ $205.15 Million |
+10.17% |
| 2011-12-31 | zł676.59 Million ≈ $186.21 Million |
-- |
About Sopharma AD
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral… Read more